Trontinemab · PrevenTRON
Roche introduced PrevenTRON for cognitively unimpaired, at-risk people. It is a prevention study, not the symptomatic TRONTIER trials or earlier Brainshuttle amyloid-clearance data. trontinemab — phase 3 study in Alzheimer's Disease. NCT07717411 lists Time to Progression, defined as confirmed Clinical Dementia Rating - Global Score (CDR-GS) > 0 as a primary outcome (Baseline up to approximately 6 years). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2032-09-03 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Long-horizon prevention study — date unconfirmed
Potential outcome market
Will trontinemab meet the prespecified primary endpoint in NCT07717411 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.